Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...

The vast majority of Roche’s oncology drugs with an orphan drug designation are expected to be blockbusters by 2025, including Perjeta (pertuzumab), Tecentriq (atezolizumab), Herceptin ...

For HER2-positive breast cancers, additions included pertuzumab, ado-trastuzumab emtansine, and neratinib. The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib were approved for HR ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Explore See latest videos, charts and news Ado YOASOBI See latest videos, charts and news Scheduled to take place March 16, 2025, at the Peacock Theater in Los Angeles, California, the event will ...

It's the latest product from ADO (A Dece Oasis), an OEM that has slowly but very surely established itself as a reputable and highly innovative company on the mid-level segment. Air 30 Ultra ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

Interventional procedures guidance Transcatheter tricuspid valve replacement for the reduction of tricuspid regurgitation Interventional procedures guidance Trastuzumab deruxtecan for adjuvant ...